Atlas Trials

Extranodal NK/T-cell Lymphoma

29 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Extranodal NK/T-cell Lymphoma

RecordFirmDate
The Whole-course Management of Pegaspargase in ENKTL (NCT05426824)The First Affiliated Hospital with Nanjing Medical University2022-07-01
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) (NCT05254899)Cancer Institute and Hospital, Chinese Academy of Medical Sciences2021-11-10
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type (NCT04414163)ImmuneOncia Therapeutics Inc.2020-10-27
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma (NCT04554511)Sun Yat-sen University2020-08-28
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL (NCT04337593)Beijing Tongren Hospital2020-06-01
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma (NCT04279379)Beijing Tongren Hospital2020-04-01
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients (NCT03671850)ViGenCell Inc.2019-04-09
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma (NCT03246750)The Thai Lymphoma Study Group2019-01-30
Tofacitinib Combined With Chidamide in R/R ENKTCL (NCT03598959)Sichuan University2019-01-01
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451)BeiGene2018-04-13
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL (NCT06406556)Sun Yat-sen University2016-03-01
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) (NCT02544425)Samsung Medical Center2016-02-21
Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma (NCT02808091)National Cancer Centre, Singapore2011-03-01
Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma (NCT01341119)Samsung Medical Center2010-11-01
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP (NCT00725231)University of Göttingen2008-02-01
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) (NCT05131438)EQRx International, Inc.

Track Extranodal NK/T-cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.